These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 17317460

  • 1. The teriparatide in the treatment of severe senile osteoporosis.
    Manuele S, Sorbello L, Puglisi N, Grasso S, La Malfa L, D'Urbino G, Rizzotto M, Strano S, Maugeri D.
    Arch Gerontol Geriatr; 2007; 44 Suppl 1():249-58. PubMed ID: 17317460
    [Abstract] [Full Text] [Related]

  • 2. Changes of the quality-of-life under the treatment of severe senile osteoporosis with teriparatide.
    Maugeri D, Russo E, Luca S, Leotta C, Mamazza G, Sorace R, Rizzotto M, Manuele S, Fiore V, Taverna G, Castiglia B, Calitro M.
    Arch Gerontol Geriatr; 2009; 49(1):35-8. PubMed ID: 18555544
    [Abstract] [Full Text] [Related]

  • 3. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT, Christensen PM, Ejersted C, Langdahl BL.
    Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
    [Abstract] [Full Text] [Related]

  • 4. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
    Chevalier Y, Quek E, Borah B, Gross G, Stewart J, Lang T, Zysset P.
    Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
    [Abstract] [Full Text] [Related]

  • 5. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD, Hanley DA, Lorraine JK, Yu M.
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK, Chadha M, Modi KD, Kumar KM, Mehrotra R, Sriram U.
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S, Marin F, Mellstrom D, Xie L, Desaiah D, Krege JH, Rosen CJ.
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [Abstract] [Full Text] [Related]

  • 9. Teriparatide (rhPTH 1-34) for the treatment of osteoporosis.
    Ebeling PR, Russell RG.
    Int J Clin Pract; 2003 Oct; 57(8):710-8. PubMed ID: 14627183
    [Abstract] [Full Text] [Related]

  • 10. Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study.
    Muscoso E, Puglisi N, Mamazza C, Lo Giudice F, Testai M, Abbate S, Santangelo A, Panebianco P, Maugeri D.
    Eur Rev Med Pharmacol Sci; 2004 Oct; 8(2):97-102. PubMed ID: 15267123
    [Abstract] [Full Text] [Related]

  • 11. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).
    Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Brixen K, Gomes JM, Obermayer-Pietsch B, Avramidis A, Sigurdsson G, Glüer CC.
    J Bone Miner Res; 2009 Apr; 24(4):726-36. PubMed ID: 19049337
    [Abstract] [Full Text] [Related]

  • 12. [Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].
    Uebelhart D, Frey D, Frey-Rindova P, Goerres G, Michel BA.
    Z Rheumatol; 2003 Dec; 62(6):512-7. PubMed ID: 14685711
    [Abstract] [Full Text] [Related]

  • 13. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis.
    Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL.
    J Bone Miner Res; 2003 Mar; 18(3):539-43. PubMed ID: 12619939
    [Abstract] [Full Text] [Related]

  • 14. Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis.
    Migliore A, Broccoli S, Massafra U, Bizzi E, Frediani B.
    Curr Med Res Opin; 2012 Mar; 28(3):467-73. PubMed ID: 22256908
    [Abstract] [Full Text] [Related]

  • 15. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.
    Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA.
    J Bone Miner Res; 2003 Jan; 18(1):9-17. PubMed ID: 12510800
    [Abstract] [Full Text] [Related]

  • 16. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.
    Dobnig H, Stepan JJ, Burr DB, Li J, Michalská D, Sipos A, Petto H, Fahrleitner-Pammer A, Pavo I.
    J Bone Miner Res; 2009 Dec; 24(12):1998-2006. PubMed ID: 19453263
    [Abstract] [Full Text] [Related]

  • 17. Treatment of osteoporosis with parathyroid hormone and teriparatide.
    Pleiner-Duxneuner J, Zwettler E, Paschalis E, Roschger P, Nell-Duxneuner V, Klaushofer K.
    Calcif Tissue Int; 2009 Mar; 84(3):159-70. PubMed ID: 19189037
    [Abstract] [Full Text] [Related]

  • 18. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 19. [Teriparatide: an anabolic drug for the treatment of patients with osteoporosis].
    Lems WF, Hamdy NA, Netelenbos JC.
    Ned Tijdschr Geneeskd; 2006 Jan 21; 150(3):132-7. PubMed ID: 16463613
    [Abstract] [Full Text] [Related]

  • 20. The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women.
    Oglesby AK, Minshall ME, Shen W, Xie S, Silverman SL.
    J Rheumatol; 2003 Jul 21; 30(7):1579-83. PubMed ID: 12858462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.